Exploring the Rapidly Evolving Landscape of Targeted Therapy for Multiple Myeloma

Donna Catamero, ANP-BC, OCN, CCRC, Mount Sinai Hospital, New York, New York, discussed the rapidly evolving treatment landscape of multiple myeloma, highlighting the shift from doublet to quadruplet therapy as standard of care in the newly diagnosed setting, with dramatic improvements in progression-free survival for both transplant-eligible and ineligible patients at the 2025 Lymphoma, Leukemia & Myeloma (LL&M) Congress APP Institute in New York, New York.

She reviewed the growing role of early CAR T-cell therapy in relapse, demonstrating benefit even in high-risk and extramedullary disease, as well as the impact of bispecific antibodies in heavily pretreated patients.

Donna concluded, “The future looks very bright for myeloma. The landscape is still changing on the horizon,” adding, “I think this is still an evolving landscape and we'll see what evolves next.”

Transcript:

Hi, I am Donna Catamero, nurse practitioner from Mount Sinai Hospital here at the LL&M APP Institute. Today I spoke about the changing landscape of multiple myeloma from treatments in the newly diagnosed setting. 

I discussed how we were once giving 2 drugs, we moved on to 3 drugs, and now standard of care across all age groups are 4 drugs. We're seeing really some amazing progression-free survival. Patients who are transplant-eligible, projected progression-free survival is approaching 17 years and for transplant-ineligible patients using quad therapies, we're looking at progression-free survivals of reaching 9 years. We're really making such improvements in the newly diagnosed setting.

Then moving on to early relapses, I discussed using CAR-T therapy early on and we're seeing benefits across all risk groups. High risk cytogenetics, extramedullary disease, we see this overall progression-free survival and overall survival with these patients getting CAR-T early on.

For our patients who are more relapsed/refractory, the use of bispecifics is really improving patients. We see the depth of responses, the duration of response, and patients who are heavily pretreated. We discussed what's on the horizon—some exciting new therapies, more CAR-T therapies, targeting different antigens or dual antigen, targeting CAR Ts, other bispecifics, and even trispecifics.

The future looks very bright for myeloma. The landscape is still changing on the horizon. Will we be able to get rid of a transplant for newly diagnosed and just use our CAR-T therapies? I think this is still an evolving landscape and we'll see what evolves next.

Source:

Catamero D. Momentum in Myeloma: Targeted Therapies Reshaping Care. Presented at Lymphoma, Leukemia & Myeloma Congress APP Institute; October 18, 2025. New York, NY.